期刊文献+

雷替曲塞联合奥沙利铂治疗晚期结直肠癌42例 被引量:2

Raltitrexed Combined With Oxaliplatin in the Treatment of 42 Cases Advanced Colorectal Cancer
下载PDF
导出
摘要 目的探讨雷替曲塞联合奥沙利铂治疗晚期结直肠癌的临床疗效。方法选取84例晚期结直肠癌患者随机分为观察组和对照组各42例,对照组采用奥沙利铂治疗,观察组采用雷替曲塞联合奥沙利铂治疗,对比两组疗效。结果观察组治疗有效率和临床获益率分别为45.24%,88.10%,高于对照组的16.67%和50.00%,观察组不良反应率21.43%,低于对照组的47.62%,差异有统计学意义(P<0.05)。结论雷替曲塞联合奥沙利铂治疗晚期结直肠癌的临床效果良好。 Objective To investigate the clinical effect of raltitrexed combined with oxaliplatin in the treatment of advanced colorectal cancer.Methods 84 cases of advanced colon rectal cancer patients were randomly divided into observation group and control group(42 cases),control group was treated with oxaliplatin,the observation group by raltitrexed combined with oxaliplatin.The efficacy of two groups were compared.Results The effective rate and clinical benefit rate of the observation group were 45.24%,88.10%,16.67% and 50%,respectively,significantly higher than the control group,the adverse reaction rate of the observation group was 21.43%,which was significantly lower than that of the control group(P〈0.05).Conclusion The clinical effect of raltitrexed combined with oxaliplatin in the treatment of advanced colorectal cancer is good.
作者 杜敏
出处 《中国继续医学教育》 2015年第28期132-133,共2页 China Continuing Medical Education
关键词 雷替曲塞 奥沙利铂 晚期结直肠癌 Raltitrexed Oxaliplatin Advanced colorectal cancer
  • 相关文献

参考文献5

二级参考文献34

  • 1杨学宁,吴一龙.实体瘤治疗疗效评价标准——RECIST[J].循证医学,2004,4(2):85-90. 被引量:1480
  • 2Weitz J, Koch M, Debus J, et al. Colorectal cancer [ J ].Lancet, 2005, 365(9454) : 153-165.
  • 3Gravalos C, Garcia-Escobar I , Garcia-Alfonso P, et al.Adjuvant chemotherapy for stages Ⅱ, Ⅲ and Ⅳof colon cancer [ J ].Clin Transl Oncol, 2009,11 ( 8 ) : 526-533.
  • 4Siegel R,Naishadham D,Jemal A. Cancer statistics,2012 [J].CA Cancer J Clin, 2012,62( 1 ) : 10-29.
  • 5Cortinovis D, Bajetta E,Di Bartolomeo M, et al. Raltitrexed plus ox- aliplatin in the treatment of metastatic colorectal cancer E J ]. Tumori, 2004,90( 2): 186-191.
  • 6Cascinu S,Graziano F,Ferrau F,et al. Raltitrexed plus oxaliplatin(TOMOX) as first-line chemotherapy for metastatic colorectal can- cer. A phase Ⅱ study of the Italian Group for the Study of Gastroin- testinal Tract Carcinomas (GISCAD) [ J ]. Ann Oncol, 2002,13 ( 5 ) : 716-720.
  • 7Scheithauer W,Kornek GV,Sehuell B,et al. Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy [J]. Ann Oncol, 2001,12 ( 5 ) : 709-714.
  • 8Gravalos C, Salut A, Garcl' a-Giro'n C, et al.A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first- line chemotherapy for advanced colorectal cancer [J ]. Clin Transl On- col, 2012,14(8) : 606-612.
  • 9Popov I, Wils J, Carrato A, et al. Final results of the PETACC- 1 trial of bolus 5-FU/LV vs raltitrexed :An unsuccessful story? [J ]. J Clin Oncol, 2008,26(15) :4053.
  • 10Popov I, Carrato A, Sobrero A, et al.Rahitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil:results from the randomised phase HI Pan-European Trial in Adjuvant Colon Cancer Ⅲ (PETAC C-i ) [J ].Eur J Cancer, 2008,44 ( 15 ) :2204-2211.

共引文献85

同被引文献14

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部